Lars Ittner

List of Publications by Year
in descending order

163	12,777	28736	29333
papers	citations	57 h-index	108 g-index

170	170	170	19013
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. Brain, 2022, 145, 1598-1609.	3.7	17
2	Developmental delay and late onset HBSL pathology in hypomorphic Dars1M256L mice. Neurochemical Research, 2022, 47, 1972-1984.	1.6	4
3	Cannabidiol (CBD) treatment improves spatial memory in 14-month-old female TAU58/2 transgenic mice. Behavioural Brain Research, 2022, 425, 113812.	1.2	13
4	Differential mitochondrial protein interaction profile between human translocator protein and its A147T polymorphism variant. PLoS ONE, 2022, 17, e0254296.	1.1	1
5	Recent progress in synthetic self-adjuvanting vaccine development. Biomaterials Science, 2022, 10, 4037-4057.	2.6	5
6	Loss of LAMP5 interneurons drives neuronal network dysfunction in Alzheimerâ€™s disease. Acta Neuropathologica, 2022, 144, 637-650.	3.9	15
7	The behavioural phenotype of 14-month-old female TAU58/2 transgenic mice. Behavioural Brain Research, 2021, 397, 112943.	1.2	5
8	Rapid initiation of cell cycle reentry processes protects neurons from amyloid-Î² toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	19
9	ALS/FTD-causing mutation in cyclin F causes the dysregulation of SFPQ. Human Molecular Genetics, 2021, 30, 971-984.	1.4	16
10	Interaction between the guanylate kinase domain of PSD-95 and the proline-rich region and microtubule binding repeats 2 and 3 of tau. Biochemistry and Cell Biology, 2021, 99, 1-11.	0.9	7
11	Syntaxins 6 and 8 facilitate tau into secretory pathways. Biochemical Journal, 2021, 478, 1471-1484.	1.7	7
12	TDP-43 and Inflammation: Implications for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. International Journal of Molecular Sciences, 2021, 22, 7781.	1.8	26
13	Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia. Communications Medicine, 2021, 1, .	1.9	14
14	The Nature of Diamino Linker and Halogen Bonding Define Selectivity of Pyrrolopyrimidine-Based LIMK1 Inhibitors. Frontiers in Chemistry, 2021, 9, 781213.	1.8	2
15	Decoupling the effects of hydrophilic and hydrophobic moieties at the neuronâ€“nanofibre interface. Chemical Science, 2020, 11, 1375-1382.	3.7	6
16	Reduction of advanced tau-mediated memory deficits by the MAP kinase p38Î³. Acta Neuropathologica, 2020, 140, 279-294.	3.9	24
17	Neurodegeneration and Motor Deficits in the Absence of Astrogliosis upon Transgenic Mutant TDP-43 Expression in Mature Mice. American Journal of Pathology, 2020, 190, 1713-1722.	1.9	1
18	Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. Scientific Reports, 2020, 10, 13741.	1.6	26

#	Article	IF	Citations
19	Tricyclic heterocycles display diverse sensitivity to the A147T TSPO polymorphism. European Journal of Medicinal Chemistry, 2020, 207, 112725.	2.6	4
20	Contribution of endogenous antibodies to learning deficits and astrocytosis in human P301S mutant tau transgenic mice. Scientific Reports, 2020, 10, 13845.	1.6	2
21	Onset of motor deficits, but not their severity, is augmented by TREM2 reduction in P301S tau transgenic mice. Alzheimer's and Dementia, 2020, 16, e040610.	0.4	0
22	Effect of polar amino acid incorporation on Fmoc-diphenylalanine-based tetrapeptides. Soft Matter, 2020, 16, 4800-4805.	1.2	5
23	Onset of hippocampal network aberration and memory deficits in P301S tau mice are associated with an early gene signature. Brain, 2020, 143, 1889-1904.	3.7	12
24	Chronic cannabidiol (CBD) treatment did not exhibit beneficial effects in 4-month-old male TAU58/2 transgenic mice. Pharmacology Biochemistry and Behavior, 2020, 196, 172970.	1.3	13
25	Reversing binding sensitivity to A147T translocator protein. RSC Medicinal Chemistry, 2020, 11, 511-517.	1.7	4
26	Programmable enzymatic oxidation of tyrosineâ€“lysine tetrapeptides. Journal of Materials Chemistry B, 2020, 8, 3104-3112.	2.9	9
27	Novel Behavioural Characteristics of Male Human P301S Mutant Tau Transgenic Mice â€“ A Model for Tauopathy. Neuroscience, 2020, 431, 166-175.	1.1	11
28	Methylation of a CGATA element inhibits binding and regulation by GATA-1. Nature Communications, 2020, 11, 2560.	5.8	21
29	K369I Tau Mice Demonstrate a Shift Towards Striatal Neuron Burst Firing and Goal-directed Behaviour. Neuroscience, 2020, 449, 46-62.	1.1	2
30	First Nondiscriminating Translocator Protein Ligands Produced from a Carbazole Scaffold. Journal of Medicinal Chemistry, 2019, 62, 8235-8248.	2.9	13
31	CNS cell typeâ€“specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. Journal of Biological Chemistry, 2019, 294, 14149-14162.	1.6	10
32	Neuroinflammation in frontotemporal dementia. Nature Reviews Neurology, 2019, 15, 540-555.	4.9	159
33	Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. International Journal of Molecular Sciences, 2019, 20, 3161.	1.8	173
34	Developmental Expression of Mutant PFN1 in Motor Neurons Impacts Neuronal Growth and Motor Performance of Young and Adult Mice. Frontiers in Molecular Neuroscience, 2019, 12, 231.	1.4	8
35	Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2019, 39, 9645-9659.	1.7	22
36	Adenoâ€associated virusâ€based Alzheimer's disease mouse models and potential new therapeutic avenues. British Journal of Pharmacology, 2019, 176, 3649-3665.	2.7	22

#	Article	IF	Citations
37	Generation of a New Tau Knockout (tauÎ”ex1) Line Using CRISPR/Cas9 Genome Editing in Mice. Journal of Alzheimer's Disease, 2018, 62, 571-578.	1.2	29
38	Epothilone D â€“ correct drug, wrong disease. Neuropathology and Applied Neurobiology, 2018, 44, 548-549.	1.8	0
39	An N-terminal motif unique to primate tau enables differential proteinâ€“protein interactions. Journal of Biological Chemistry, 2018, 293, 3710-3719.	1.6	53
40	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain, 2018, 141, 521-534.	3.7	114
41	Selective Spatiotemporal Vulnerability of Central Nervous System Neurons to Pathologic TAR DNA-Binding Protein 43 in Aged Transgenic Mice. American Journal of Pathology, 2018, 188, 1447-1456.	1.9	8
42	Physiological changes in neurodegeneration â€” mechanistic insights and clinical utility. Nature Reviews Neurology, 2018, 14, 259-271.	4.9	72
43	Absence of IL-6 prevents corneal wound healing after deep excimer laser ablation in vivo. Eye, 2018, 32, 156-157.	1.1	6
44	Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy. Acta Neuropathologica, 2018, 135, 95-113.	3.9	38
45	Neuronal MAP kinase p38Î± inhibits c-Jun N-terminal kinase to modulate anxiety-related behaviour. Scientific Reports, 2018, 8, 14296.	1.6	27
46	Glyoxylamide-based self-assembly hydrogels for sustained ciprofloxacin delivery. Journal of Materials Chemistry B, 2018, 6, 6089-6098.	2.9	16
47	Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice. Neurobiology of Disease, 2018, 120, 76-87.	2.1	16
48	Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration: Mouse Models. , 2018, , 187-219.		1
49	Peptide Nanofiber Substrates for Long-Term Culturing of Primary Neurons. ACS Applied Materials & Interfaces, 2018, 10, 25127-25134.	4.0	16
50	Dendritic Tau in Alzheimerâ€™s Disease. Neuron, 2018, 99, 13-27.	3.8	178
51	In vivo characterization of the aspartyl-tRNA synthetase DARS: Homing in on the leukodystrophy HBSL. Neurobiology of Disease, 2017, 97, 24-35.	2.1	20
52	ALS/FTLD: experimental models and reality. Acta Neuropathologica, 2017, 133, 177-196.	3.9	78
53	The Polyphenol Altenusin Inhibits in Vitro Fibrillization of Tau and Reduces Induced Tau Pathology in Primary Neurons. ACS Chemical Neuroscience, 2017, 8, 743-751.	1.7	32
54	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. Neuroscience and Biobehavioral Reviews, 2017, 74, 126-138.	2.9	23

#	Article	IF	Citations
55	The Link between Type 2 Diabetes and Neurodegeneration: Roles for Amyloid-Î², Amylin, and Tau Proteins. Journal of Alzheimer's Disease, 2017, 59, 421-432.	1.2	154
56	Accelerated aging exacerbates a preâ€existing pathology in a tau transgenic mouse model. Aging Cell, 2017, 16, 377-386.	3.0	29
57	Ring-opened aminothienopyridazines as novel tau aggregation inhibitors. MedChemComm, 2017, 8, 1275-1282.	3.5	7
58	TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway. Human Molecular Genetics, 2017, 26, 1732-1746.	1.4	62
59	Tau exacerbates excitotoxic brain damage in an animal model of stroke. Nature Communications, 2017, 8, 473.	5.8	134
60	Assessment of amyloid Î² in pathologically confirmed frontotemporal dementia syndromes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 10-20.	1.2	38
61	Generation of Genetically Modified Mice through the Microinjection of Oocytes. Journal of Visualized Experiments, 2017, , .	0.2	10
62	Alzheimerâ€™s Disease: Insights from Genetic Mouse Models and Current Advances in Human IPSC-Derived Neurons. Advances in Neurobiology, 2017, 15, 3-29.	1.3	4
63	Multiple Mechanisms Linking Type 2 Diabetes and Alzheimerâ€™s Disease: Testosterone as a Modifier. Journal of Alzheimer's Disease, 2017, 59, 445-466.	1.2	36
64	Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination. MedChemComm, 2017, 8, 202-210.	3.5	12
65	Mutations in tropomyosin 4 underlie a rare form of human macrothrombocytopenia. Journal of Clinical Investigation, 2017, 127, 814-829.	3.9	57
66	Neuronal network disintegration: common pathways linking neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1234-1241.	0.9	106
67	PDGF-AB and 5-Azacytidine induce conversion of somatic cells into tissue-regenerative multipotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2306-15.	3.3	40
68	Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease. Neurobiology of Aging, 2016, 48, 135-142.	1.5	63
69	Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia. Neuroscience Letters, 2016, 631, 24-29.	1.0	34
70	Motor cortical function determines prognosis in sporadic ALS. Neurology, 2016, 87, 513-520.	1.5	76
71	Site-specific phosphorylation of tau inhibits amyloid-Î² toxicity in Alzheimerâ€™s mice. Science, 2016, 354, 904-908.	6.0	241
72	Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. Lancet Neurology, The, 2016, 15, 332-342.	4.9	120

#	Article	IF	Citations
73	The frontotemporal dementia-motor neuron disease continuum. Lancet, The, 2016, 388, 919-931.	6.3	294
74	A Comparative Study of Variables Influencing Ischemic Injury in the Longa and Koizumi Methods of Intraluminal Filament Middle Cerebral Artery Occlusion in Mice. PLoS ONE, 2016, 11, e0148503.	1.1	96
75	No Overt Deficits in Aged Tau-Deficient C57Bl/6.Mapttm1(EGFP)Kit GFP Knockin Mice. PLoS ONE, 2016, 11, e0163236.	1.1	35
76	Near infrared light mitigates cerebellar pathology in transgenic mouse models of dementia. Neuroscience Letters, 2015, 591, 155-159.	1.0	55
77	Tauâ€targeting passive immunization modulates aspects of pathology in tau transgenic mice. Journal of Neurochemistry, 2015, 132, 135-145.	2.1	70
78	The impact of luteinizing hormone and testosterone on beta amyloid (AÎ²) accumulation: Animal and human clinical studies. Hormones and Behavior, 2015, 76, 81-90.	1.0	25
79	Earlyâ€onset axonal pathology in a novel <scp>P</scp>301<scp>S</scp>â€<scp>T</scp>au transgenic mouse model of frontotemporal lobar degeneration. Neuropathology and Applied Neurobiology, 2015, 41, 906-925.	1.8	41
80	FTD and ALSâ€"translating mouse studies into clinical trials. Nature Reviews Neurology, 2015, 11, 360-366.	4.9	64
81	Amyotrophic lateral sclerosis-associated mutant profilin 1 increases dendritic arborisation and spine formation in primary hippocampal neurons. Neuroscience Letters, 2015, 609, 223-228.	1.0	14
82	First Demonstration of Positive Allosteric-like Modulation at the Human Wild Type Translocator Protein (TSPO). Journal of Medicinal Chemistry, 2015, 58, 8743-8749.	2.9	12
83	Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathologica, 2015, 130, 661-678.	3.9	61
84	AÎ²-dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimerâ€™s disease. Nature Communications, 2015, 6, 8836.	5.8	70
85	Tau aggregation and its interplay with amyloid-Î². Acta Neuropathologica, 2015, 129, 207-220.	3.9	283
86	ERK inhibition with PD184161 mitigates brain damage in a mouse model of stroke. Journal of Neural Transmission, 2014, 121, 543-7.	1.4	20
87	The translocator protein as a drug target in Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2014, 14, 439-448.	1.4	20
88	p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2014, 2, 149.	2.4	65
89	Inducible, tightly regulated and non-leaky neuronal gene expression in mice. Transgenic Research, 2014, 23, 225-233.	1.3	18
90	The nucleotide exchange factor SIL1 is required for glucose-stimulated insulin secretion from mouse pancreatic beta cells in vivo. Diabetologia, 2014, 57, 1410-1419.	2.9	22

#	Article	IF	Citations
91	Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration: Mouse Models. , 2014, , 111-129.		0
92	Slow Excitotoxicity in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 643-668.	1.2	82
93	Glutamate Metabolism is Impaired in Transgenic Mice with Tau Hyperphosphorylation. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 684-691.	2.4	54
94	Alzheimer's disease models and functional genomicsâ€"How many needles are there in the haystack?. Frontiers in Physiology, 2012, 3, 320.	1.3	18
95	Evidence for Complex Binding Profiles and Species Differences at the Translocator Protein (TSPO) (18) Tj ETQq1 1 0.784314 rgBT /Over	0.6	18
96	Lessons from Tau-Deficient Mice. International Journal of Alzheimer's Disease, 2012, 2012, 1-8.	1.1	99
97	Tau Protein: Function and Pathology. International Journal of Alzheimer's Disease, 2012, 2012, 1-2.	1.1	5
98	Tauâ€targeted treatment strategies in Alzheimer's disease. British Journal of Pharmacology, 2012, 165, 1246-1259.	2.7	114
99	MicroRNA networks surrounding APP and amyloid-Î² metabolism â€" Implications for Alzheimer's disease. Experimental Neurology, 2012, 235, 447-454.	2.0	90
100	Tau-Mediated Nuclear Depletion and Cytoplasmic Accumulation of SFPQ in Alzheimer's and Pick's Disease. PLoS ONE, 2012, 7, e35678.	1.1	82
101	Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice. PLoS ONE, 2011, 6, e26860.	1.1	142
102	Inhibition of the Mitochondrial Enzyme ABAD Restores the Amyloid-Î²-Mediated Deregulation of Estradiol. PLoS ONE, 2011, 6, e28887.	1.1	49
103	Amyloid-Î² and tau â€" a toxic pas de deux in Alzheimer's disease. Nature Reviews Neuroscience, 2011, 12, 67-72.	4.9	1,147
104	Modes of AÎ² toxicity in Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2011, 68, 3359-3375.	2.4	78
105	Brief update on different roles of tau in neurodegeneration. IUBMB Life, 2011, 63, 495-502.	1.5	42
106	ENU Mutagenesis Screen to Establish Motor Phenotypes in Wild-Type Mice and Modifiers of a Pre-Existing Motor Phenotype in Tau Mutant Mice. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-11.	3.0	8
107	Cytoplasmic Accumulation and Aggregation of TDP-43 upon Proteasome Inhibition in Cultured Neurons. PLoS ONE, 2011, 6, e22850.	1.1	91
108	Gateway-compatible lentiviral transfer vectors for ubiquitin promoter driven expression of fluorescent fusion proteins. Plasmid, 2010, 63, 155-160.	0.4	11

#	Article	IF	Citations
109	AÎ² and human amylin share a common toxicity pathway via mitochondrial dysfunction. Proteomics, 2010, 10, 1621-1633.	1.3	112
110	Neuronal MicroRNA Deregulation in Response to Alzheimer's Disease Amyloid-Î². PLoS ONE, 2010, 5, e11070.	1.1	183
111	Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13888-13893.	3.3	237
112	Dissecting Toxicity of Tau and Î²-Amyloid. Neurodegenerative Diseases, 2010, 7, 10-12.	0.8	25
113	Animal models reveal role for tau phosphorylation in human disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 860-871.	1.8	67
114	Dendritic Function of Tau Mediates Amyloid-Î² Toxicity in Alzheimer's Disease Mouse Models. Cell, 2010, 142, 387-397.	13.5	1,563
115	Experimental Diabetes Mellitus Exacerbates Tau Pathology in a Transgenic Mouse Model of Alzheimer's Disease. PLoS ONE, 2009, 4, e7917.	1.1	161
116	Amyloid-Î² and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20057-20062.	3.3	581
117	Phosphorylated Tau Interacts with c-Jun N-terminal Kinase-interacting Protein 1 (JIP1) in Alzheimer Disease. Journal of Biological Chemistry, 2009, 284, 20909-20916.	1.6	139
118	Phosphorylation of soluble tau differs in Pickâ€™s disease and Alzheimerâ€™s disease brains. Journal of Neural Transmission, 2009, 116, 1243-1251.	1.4	35
119	Response to the comment â€˜Iron, type 2 diabetes mellitus, and Alzheimerâ€™s diseaseâ€™ to our Visions and Reflections article â€˜Common features between diabetes mellitus and Alzheimerâ€™s diseaseâ€™. Cellular and Molecular Life Sciences, 2009, 66, 2945-2945.	2.4	0
120	Common features between diabetes mellitus and Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2009, 66, 1321-1325.	2.4	100
121	Primary support cultures of hippocampal and substantia nigra neurons. Nature Protocols, 2009, 4, 78-85.	5.5	185
122	The Translocator Protein (18 kDa): Central Nervous System Disease and Drug Design. Journal of Medicinal Chemistry, 2009, 52, 581-592.	2.9	92
123	Substrate-specific reduction of PP2A activity exaggerates tau pathology. Biochemical and Biophysical Research Communications, 2009, 379, 400-405.	1.0	36
124	Alzheimer's Disease Selective Vulnerability and Modeling in Transgenic Mice. Journal of Alzheimer's Disease, 2009, 18, 243-251.	1.2	29
125	Animal models of Alzheimer's disease and frontotemporal dementia. Nature Reviews Neuroscience, 2008, 9, 532-544.	4.9	604
126	Divergent phosphorylation pattern of tau in P301L tau transgenic mice. European Journal of Neuroscience, 2008, 28, 137-147.	1.2	76

#	Article	IF	Citations
127	Human but not rat amylin shares neurotoxic properties with AÎ²42 in longâ€term hippocampal and cortical cultures. FEBS Letters, 2008, 582, 2188-2194.	1.3	64
128	Brain Area-Specific Effect of TGF-Î² Signaling on Wnt-Dependent Neural Stem Cell Expansion. Cell Stem Cell, 2008, 2, 472-483.	5.2	123
129	Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15997-16002.	3.3	201
130	Functional Genomics Dissects Pathomechanisms in Tauopathies: Mitosis Failure and Unfolded Protein Response. Neurodegenerative Diseases, 2008, 5, 179-181.	0.8	9
131	Transgenic mice with ocular overexpression of an adrenomedullin receptor reflect human acute angle-closure glaucoma. Clinical Science, 2008, 114, 49-58.	1.8	18
132	Is Tau Aggregation Toxic or Protective: A Sensible Question in the Absence of Sensitive Methods?. Journal of Alzheimer's Disease, 2008, 14, 423-429.	1.2	31
133	An update on the toxicity of Aβ in Alzheimer’s disease. Neuropsychiatric Disease and Treatment, 2008, 4, 1033.	1.0	32
134	Calcitonin gene-related peptide-evoked sustained tachycardia in calcitonin receptor-like receptor transgenic mice is mediated by sympathetic activity. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2155-H2160.	1.5	10
135	Wnt/BMP signal integration regulates the balance between proliferation and differentiation of neuroepithelial cells in the dorsal spinal cord. Developmental Biology, 2007, 304, 394-408.	0.9	97
136	Interaction of receptor-activity-modifying protein1 with tubulin. Biochimica Et Biophysica Acta - General Subjects, 2007, 1770, 1145-1150.	1.1	8
137	Pronuclear injection for the production of transgenic mice. Nature Protocols, 2007, 2, 1206-1215.	5.5	159
138	Continuous expression of the homeobox gene Pax6 in the ageing human retina. Eye, 2007, 21, 90-93.	1.1	31
139	A Decade of Tau Transgenic Animal Models and Beyond. Brain Pathology, 2007, 17, 91-103.	2.1	145
140	Impact of Î²-Amyloid on the Tau Pathology in Tau Transgenic Mouse and Tissue Culture Models. , 2007, , 198-215.		0
141	Self-assembly of sensory neurons into ganglia-like microtissues. Journal of Biotechnology, 2006, 121, 86-101.	1.9	34
142	Tissue-Transplant Fusion and Vascularization of Myocardial Microtissues and Macrotissues Implanted into Chicken Embryos and Rats. Tissue Engineering, 2006, 12, 2541-2553.	4.9	58
143	Impaired development of the Harderian gland in mutant protein phosphatase 2A transgenic mice. Mechanisms of Development, 2006, 123, 362-371.	1.7	15
144	Design of Custom-Shaped Vascularized Tissues Using Microtissue Spheroids as Minimal Building Units. Tissue Engineering, 2006, 12, 2151-2160.	4.9	146

#	Article	IF	Citations
145	Altered phosphorylation of cytoskeletal proteins in mutant protein phosphatase 2A transgenic mice. Biochemical and Biophysical Research Communications, 2006, 343, 1171-1178.	1.0	37
146	Altered levels of PP2A regulatory B/PR55 isoforms indicate role in neuronal differentiation. International Journal of Developmental Neuroscience, 2006, 24, 437-443.	0.7	15
147	Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy?. Medical Journal of Australia, 2006, 185, 381-384.	0.8	27
148	Î²-Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics, 2006, 6, 6566-6577.	1.3	62
149	Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?. Journal of Neurochemistry, 2006, 98, 993-1006.	2.1	113
150	DiGeorge syndrome and pharyngeal apparatus development. BioEssays, 2006, 28, 1078-1086.	1.2	47
151	Enhanced Vascular Responses to Adrenomedullin in Mice Overexpressing Receptor-Activityâ€“Modifying Protein 2. Circulation Research, 2006, 98, 262-270.	2.0	50
152	Design of Custom-Shaped Vascularized Tissues Using Microtissue Spheroids as Minimal Building Units. Tissue Engineering, 2006, .	4.9	0
153	Tissue-Transplant Fusion and Vascularization of Myocardial Microtissues and Macrotissues Implanted into Chicken Embryos and Rats. Tissue Engineering, 2006, .	4.9	1
154	Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nature Medicine, 2005, 11, 138-145.	15.2	356
155	Compound developmental eye disorders following inactivation of TGFbeta signaling in neural-crest stem cells. Journal of Biology, 2005, 4, 11.	2.7	110
156	Inactivation of TGFÂ signaling in neural crest stem cells leads to multiple defects reminiscent of DiGeorge syndrome. Genes and Development, 2005, 19, 530-535.	2.7	134
157	Neural crest stem cell maintenance by combinatorial Wnt and BMP signaling. Journal of Cell Biology, 2005, 169, 309-320.	2.3	176
158	VEGF profiling and angiogenesis in human microtissues. Journal of Biotechnology, 2005, 118, 213-229.	1.9	81
159	The N-Terminal Extracellular Domain 23â^'60 of the Calcitonin Receptor-Like Receptor in Chimeras with the Parathyroid Hormone Receptor Mediates Association with Receptor Activity-Modifying Protein 1â€. Biochemistry, 2005, 44, 5749-5754.	1.2	46
160	Role of the protein tau in Alzheimer's disease. Drug Discovery Today Disease Mechanisms, 2005, 2, 395-400.	0.8	1
161	Selective Inactivation of Adrenomedullin over Calcitonin Gene-related Peptide Receptor Function by the Deletion of Amino Acids 14-20 of the Mouse Calcitonin-like Receptor. Journal of Biological Chemistry, 2004, 279, 20387-20391.	1.6	26
162	Aspartate69 of the calcitonin-like receptor is required for its functional expression together with receptor-activity-modifying proteins 1 and -2. Biochemical and Biophysical Research Communications, 2004, 319, 1203-1209.	1.0	20

#	Article	IF	Citations
163	Circulating procalcitonin and cleavage products in septicaemia compared with medullary thyroid carcinoma. European Journal of Endocrinology, 2002, 147, 727-731.	1.9	17